(NASDAQ:ADPT), SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced growing interventional use of its clonoSEQ(R) test among the 90 abstracts featuring clonoSEQ data at the 67th […]

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ(R) Data Driving Treatment Interventions at 2025 ASH Annual Meeting GlobeNewswire December 06, 2025 SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Sprouts to Contact Him Directly to Discuss Their Options If you purchased or acquired securities in Sprouts between June 4, 2025 and October 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Marex to Contact Him Directly to Discuss Their Options If you purchased or acquired securities in Marex between May 16, 2024 and August 5, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Alexandria to Contact Him Directly to Discuss Their Options If you purchased or acquired securities in Alexandria between January 27, 2025 and October 27, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh

(NASDAQ:ARVN), – Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial to evaluate ARV-393 plus glofitamab as a chemotherapy-free combination approach in diffuse large B-cell lymphoma (DLBCL); initiation expected in 2026 – NEW HAVEN, Conn., Dec. 06, 2025 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating

SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) — Io Therapeutics, Inc., a privately held pharmaceutical company headquartered in Spring, Texas; announced today collaborative presentations at the 67th American Society of Hematology Annual Meeting and Exposition, in Orlando, Florida; with scientists from the Duke University School of Medicine in Durham, North Carolina; reporting data from preclinical

Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition GlobeNewswire December 06, 2025 – Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial to evaluate ARV-393 plus glofitamab as a

Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company's RXR agonist compound IRX4204 has synergistic efficacy against human multiple myeloma GlobeNewswire December 06, 2025 SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) — Io Therapeutics, Inc., a privately held pharmaceutical company

(NASDAQ:COST), 240 JOBS CREATED, THOUSANDS OF UNIQUE ITEMS TAILORED TO BUSINESS NEEDS EAST GWILLIMBURY, Ontario, Dec. 06, 2025 (GLOBE NEWSWIRE) — Costco Wholesale opened its tenth Canadian Business Centre today, located at 18182 Yonge Street, south of York Regional Rd 19. The 137,000 square-foot facility is a conversion of the original Costco Newmarket which recently